LearnGlossaryMarketStocksSuperinvestorsSign in

CTSO

Cytosorbents Corporation

Healthcare · $13M market cap

Verdict

We can't put a fair value on CTSO right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-3.5% a year✗
Sales growth25.4% a year✓
Free cash flow growth—?
Return on invested capital-51.2%✗

Follow CTSO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: 1 open-market purchase worth $70K. Why purchases matter

Purchases

Chan Phillip P.

Chief Executive Officer · 2026-09-04

Bought

$70K

About Cytosorbents Corporation

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works